A multicentre case-control study of nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock
Annick Legras(Université de Tours), E. Autret‐Leca(Université de Tours), J. Tayoro(Centre Hospitalier du Mans), A.‐P. Jonville‐Béra(Université de Tours), Anne Veinstein, Bruno Giraudeau(Inserm), Bruno François(Inserm), D. Villers(Centre Hospitalier Universitaire de Nantes), Achille Kouatchet(Oslo University Hospital), Isabelle Runge, Christophe Camus(Centre Hospitalier Universitaire de Rennes)
Cited by 53
Related Papers
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
|New England Journal of Medicine|2018|894
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890